Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer

Volumn 113, Issue 7, 2008, Pages 1666-1675

  Holmes, Jarrod P ^a   Gates, Jeremy D ^b   Benavides, Linda C ^b   Hueman, Matthew T ^c   Carmichael, Mark G ^c,d   Patil, Ritesh ^e   Craig, Dianna ^e   Mittendorf, Elizabeth A ^f   Stojadinovic, Alexander ^c   Ponniah, Sathibalan ^c   Peoples, George E ^b,c  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e Windber Medical Center   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Dosing; E75; Peptide; Vaccine

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HER 2 PEPTIDE E75 (369 377), HUMAN; HER-2 PEPTIDE E75 (369-377), HUMAN; PEPTIDE FRAGMENT; SUBUNIT VACCINE;

ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; FEMALE; HUMAN; IMMUNOLOGY; MIDDLE AGED; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CANCER VACCINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 54049092448     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23772     Document Type: Article

References (34)

1. Meric F, Hung MC, Hortobagyi GN, et al. HER2/neu in the management of invasive breast cancer. J Am Coll Surg. 2002;194:488-501. (Pubitemid 34274845)
2. Ioannides CG, Fisk B, Fan D, et al. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol. 1993;151:225-234. (Pubitemid 23308446)
3. Yoshino I, Peoples GE, Goedegebuure PS, et al. HER2/neuderived peptides are shared antigens among human nonsmall cell lung cancer and ovarian cancer. Cancer Res. 1994;54:3387-3390. (Pubitemid 24225955)
4. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T-cells specific for peptide derived from the HER-2/neu protooncogene protein. Cancer Res. 1994;54:1071-1076. (Pubitemid 24085465)
5. Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol. 2005;36:250-261. (Pubitemid 40404008)
6. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1533-1541.
7. Peoples GE, Goedegeburre PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA. 1995;92:432-436.
8. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of the HER-2/neu protooncogene recognized by ovarian tumor-specific CTL lines. J Exp Med. 1995;181:2109-2117.
9. Anderson BW, Peoples GE, Murray JL, et al. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res. 2000;6:4192-4200.
10. Lustgarten J, Theobald M, Labadie C, et al. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD. 8. Hum Immunol. 1997;52:109-118. (Pubitemid 27147134)
11. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998;58:4902-4908. (Pubitemid 28503688)
12. Knutson KL, Schiffman K, Cheever MA, et al. Immunization of cancer patients with HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res. 2002;8:1014-1018. (Pubitemid 34517634)
13. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E74 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002;8:3407-3418. (Pubitemid 35340715)
14. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cell cancer induces immunological responses. Clin Cancer Res. 2004; 10:4699-4708. (Pubitemid 38955520)
15. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96:3102-3108.
16. Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res. 2002;8:3394-3400. (Pubitemid 35340713)
17. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002;20:2624-2632. (Pubitemid 34575634)
18. Disis ML, Grabstein KH, Sleath PR, et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res. 1999;5:1289-1297. (Pubitemid 29282931)
19. HuemanMT, Dehqanzada ZA,Novak TE, et al. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients. Clin Cancer Res. 2005;11:7470-7479. (Pubitemid 41507708)
20. Peoples GE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005;23:7536-7545. (Pubitemid 46291817)
21. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-01&I-02. Clin Cancer Res. 2008;14:797-803. (Pubitemid 351231162)
22. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
23. Rammensee HG, Bachmann J, Stevanovic S. MHC Ligands and Peptide Motifs. New York: Springer; 1997.
24. Woll M, Fisher CM, Ryan GB, et al. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER/neuvaccine in breast and prostate cancer patients. J Clin Immunol. 2004;24:449-461. (Pubitemid 39005578)
25. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med. 1975;293:501-502.
26. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007;30:1-15. (Pubitemid 46052199)
27. Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18:226-232. (Pubitemid 46323086)
28. Schaed SG, Klimek VM, Panageas KS, et al. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colonystimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2002;8:967-972. (Pubitemid 34517629)
29. Slingluff CL, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474-4485. (Pubitemid 41185113)
30. Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGEA1-,MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol. 2005;174:3080-3086. (Pubitemid 40279730)
31. Slingluff CL, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using 4 melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016-4026. (Pubitemid 46606217)
32. Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine. J Clin Oncol. 2004;22:1916-1925. (Pubitemid 41095184)
33. Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res. 2006;12:2342s-2345s.
34. Berzofsky JA, Oh S, Terabe M. Peptide vaccines against cancer. Cancer Treat Res. 2005;123:115-136.